{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Abida W"],"funding":["National Cancer Institute","NCI NIH HHS"],"pagination":["1111-1120"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10947849"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(6)"],"pubmed_abstract":["<h4>Purpose</h4>Increased glucocorticoid receptor (GR) signaling is a proposed compensatory mechanism of resistance to androgen receptor (AR) inhibition in metastatic castration-resistant prostate cancer (mCRPC). ORIC-101 is a potent and selective orally-bioavailable GR antagonist.<h4>Patients and methods</h4>Safety, pharmacokinetic/pharmacodynamic, and antitumor activity of ORIC-101 in combination with enzalutamide were studied in patients with mCRPC progressing on enzalutamide. ORIC-101 doses ranging from 80 to 240 mg once daily were tested in combination with enzalutamide 160 mg once daily. Pharmacokinetics/pharmacodynamics was assessed after a single dose and at steady state. Disease control rate (DCR) at 12 weeks was evaluated at the recommended phase 2 dose (RP2D).<h4>Results</h4>A t"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide."],"pmcid":["PMC10947849"],"funding_grant_id":["P30 CA008748","P30-CA008748"],"pubmed_authors":["Agarwal N","Wang A","Multani PS","Hahn AW","Rettig M","Xu R","Logothetis CJ","Smith MR","Sieber P","Wang J","Chow Maneval E","Junttila MR","Barkund S","Pankov A","Morris MJ","Dorff T","Duff M","Shore N","Patel R","Abida W","Page A","Daemen A","Monk P"],"additional_accession":[]},"is_claimable":false,"name":"Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide.","description":"<h4>Purpose</h4>Increased glucocorticoid receptor (GR) signaling is a proposed compensatory mechanism of resistance to androgen receptor (AR) inhibition in metastatic castration-resistant prostate cancer (mCRPC). ORIC-101 is a potent and selective orally-bioavailable GR antagonist.<h4>Patients and methods</h4>Safety, pharmacokinetic/pharmacodynamic, and antitumor activity of ORIC-101 in combination with enzalutamide were studied in patients with mCRPC progressing on enzalutamide. ORIC-101 doses ranging from 80 to 240 mg once daily were tested in combination with enzalutamide 160 mg once daily. Pharmacokinetics/pharmacodynamics was assessed after a single dose and at steady state. Disease control rate (DCR) at 12 weeks was evaluated at the recommended phase 2 dose (RP2D).<h4>Results</h4>A t","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-06-02T04:58:06.246Z","creation":"2025-04-04T02:04:57.451Z"},"accession":"S-EPMC10947849","cross_references":{"pubmed":["38226958"],"doi":["10.1158/1078-0432.ccr-23-3508","10.1158/1078-0432.CCR-23-3508"]}}